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doi:10.1016/j.jtcvs.2008.01.017Objectives: To address the present controversy regarding optimal management of
status 2 heart transplant candidates, we studied the short- and long-term fate of med-
ically improved patients removed from our transplant waiting list to assess return of
heart failure and occurrence of sudden cardiac death, identify interventions to improve
outcomes, and compare their survival with that of similar transplanted patients.
Methods: From January 1985 to February 2004, 100 status 2 patients were delisted for
medical improvement (median on-list duration, 314 days). Return of heart failure,
sudden cardiac death, and all-cause mortality were determined from follow-up
(mean, 7.76 3.9 years among survivors; 10% followed.12 years). Hazard function
modeling, competing-risks analyses, simulation, and propensity matching to equiva-
lent patients undergoing transplantation were used to analyze and compare outcomes
and predict benefit of interventions.
Results: Freedom from return of heart failure was 77% at 5 years. The most common
mode of death was sudden cardiac death, with risk peaking at 2.5 years after delisting
but remaining at 3.5% per year thereafter. Event-free survival at 1, 5, and 10 years was
94%, 55%, and 28%, respectively; simulation demonstrated that implantable cardi-
overter–defibrillators could have improved this to 45% at 10 years. Overall survival
after delisting was better than that of matched status 2 patients who underwent trans-
plantation, but was demonstrably worse after 30 months.
Conclusions: Status 2 patients, including those delisted, require vigilant surveillance
and optimal medical management, implantable cardioverter–defibrillators, and a re-
vised approach to transplantation timing, such that overall salvage is maximized while
allocation of scarce organs is optimized.
C
ardiac transplantation has long been thought to be the most appropriate ther-
apeutic option for patients with end-stage heart failure, but with the prolifer-
ation of life-extending alternative medical and surgical therapies of the past
decade, this thinking might no longer be valid. Indeed, an increasing body of obser-
vational evidence casts doubt on a clear benefit of cardiac transplantation for Unified
Network for Organ Sharing (UNOS) status 2 outpatients receiving optimal medical
therapy.1,2 To date, however, these reports are limited by short-term follow-up. Al-
though a randomized trial of transplantation versus medical therapy for such patients
has been proposed, it is unlikely to be undertaken.3,4The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1159
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ICD 5 implantable cardioverter–defibrillator
NYHA 5 New York Heart Association
SCD 5 sudden cardiac death
UNOS 5 Unified Network for Organ Sharing
_VO2 5 peak oxygen consumption
In the absence of such a trial, we sought to augment short-
term data with long-term information by studying the fate of
status 2 patients removed over the years from our heart trans-
plant waiting list (delisted) because of medical improvement.
We considered such patients as surrogates for medical ther-
apy versus transplantation in stable outpatients with chronic
heart failure. Specifically assessed were return of heart failure
and occurrence of sudden cardiac death (SCD), interventions
to improve outcomes, and survival compared with that of sta-
tus 2 patients undergoing transplantation.
Materials and Methods
Patients
From January 1, 1985, to February 1, 2004, 229 patients were re-
moved (delisted) from Cleveland Clinic’s cardiac transplant waiting
list for alternative nontransplantation operations (n 5 70), psycho-
social factors (n5 30), medical contraindications to transplantation
(n 5 29), and medical improvement (n 5 100). This last group of
100 patients, all of whomwere in UNOS status 2 at delisting, formed
the study cohort. Patients transferred to other cardiac transplant pro-
grams were not considered delisted.
Cases were identified through the Cleveland Clinic Unified
Transplant Database, which is used for UNOS reporting and has
been approved for use in research by the institutional review board,
with patient consent waived. These data were confirmed and supple-
mented by review of each patient’s clinical records to determine the
reason for delisting, time on the waiting list, UNOS status and New
York Heart Association (NYHA) functional class at delisting, and,
when available, peak oxygen consumption ( _VO2) during exercise
at listing and delisting.
Clinical characteristics of patients at listing and delisting are pre-
sented in Table 1. Of this group, 91% were aggressively treated with
optimal medical therapy for a minimum of 9 months before listing.
Despite optimal medical therapy, persistent NYHA class III or IV
symptoms and _VO2 of less than 14mL $ kg
21 $min21 guided the de-
cision to list potential transplant candidates. The remaining patients
were admitted with cardiogenic shock requiring mechanical circula-
tory support and listed for transplantation within a week of referral.
Substantial subjective clinical improvement in NYHA class oc-
curred in 86% of delisted patients, and there was an objective im-
provement in mean _VO2 from 14 6 3.3 to 19 6 3.2 mL $ kg
21 $
min21 at delisting. Mean age at delisting was 526 11 years (range,
26–73 years with 9% .age 65 years); 82% were men (Table 1).
Median time on the waiting list was 314 days. Diagnoses were
about equally divided between dilated and ischemic cardiomyopa-
thy. Of note, malignant ventricular dysrhythmias were a common
occurrence while these patients were on the waiting list.1160 The Journal of Thoracic and Cardiovascular Surgery c MaDefinitions and Indications
Medically improved patients were those who were in UNOS status
2 for more than 6 months with objective improvement in NYHA
class (all but 1 known to be in NYHA class I or II at delisting, Ta-
ble 1). Indications for delisting were improved _VO2 during exer-
cise from listing to delisting, subjective improvement in heart
failure symptoms, and a heart failure team consensus that cardiac
transplantation would not provide a survival benefit over medical
management. No formal surveillance program was implemented;
rather, patients were remanded to the care of their local health
care providers.
Outcomes
Patients or their surviving families were followed cross-sectionally
by using an institutional review board–approved telephone script,
with a common closing date of September 15, 2005. Follow-up
TABLE 1. Characteristics of patients delisted for medical








UNOS status at listing
1 20
2 80





Peak _VO2 at listing (mean 6 SD, n 5 34) 13.7 6 3.3
Atrial fibrillation or flutter during listing 41
Ventricular dysrhythmias during listing
Sudden cardiac death 14
Ventricular fibrillation 4
Ventricular tachycardia 48
Complete heart block 3
Mechanical circulatory support during listing 9




Time on waiting list (d; median [15th–85th
percentiles])
314 (96–831)





Peak _VO2 at delisting (mean 6 SD, n 5 22) 19.4 6 3.2
UNOS, Unified Network for Organ Sharing; NYHA, New York Heart Associ-
ation; _VO2, peak oxygen consumption; SD, standard deviation.y 2008
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survivors; 10%were followedmore than 12 years. Outcomes elicited
included (1) return of heart failure, defined as return of NYHA class
IV heart failure symptoms, relisting for transplantation, institution of
mechanical circulatory support, or reported death in heart failure; (2)
mode of death (heart failure, SCD, or noncardiac death); (3) insertion
of an implantable cardioverter–defibrillator (ICD) among the 99
patients not having such a device inserted before delisting; and (4)
all-cause mortality at any time during follow-up.
Data Analysis
All time-related post-delisting events were analyzed nonparametri-
cally by using the method of Kaplan and Meier and parametrically
by multiphase hazard modeling.5 (For additional details, see
http://www.clevelandclinic.org/heartcenter/hazard.) Multivariable
analysis of outcomes was performed in the hazard function domain
by using bagging as the primary variable selection method.6,7 For
this, 1000 bootstrap data sets were analyzed with a selection crite-
rion of P 5 .05, followed by aggregation of models by the median
rule. Variables used in these analyses were age at delisting (and its
potential linearizing transformations of scale), sex, race, indication
for listing (ischemic vs dilated cardiomyopathy vs other), dysrhyth-
mia during listing (atrial fibrillation or flutter, sustained ventricular
tachycardia, and SCD), NYHA class at listing and delisting,
UNOS status at listing, time on the waiting list, and date of
delisting, expressed as the interval between 1985 and delisting.
Event-free survival was defined as freedom from 3 end states:
return of heart failure, SCD, and all other modes of death, each cen-
sored at any subsequent transplantation. Nonparametric simulta-
neous estimation of cumulative incidence for these events used
the multiple decrement method of Andersen and colleagues.8 For
parametric estimation, rate of transition (hazard function) from
event-free survival to each end state was estimated, and event-free
survival and cumulative incidence of end states were calculated
by using numeric integration. To estimate the potential benefit of
ICD insertion, we simulated event-free survival were SCD com-
pletely eliminated.
Survival after delisting for medical improvement was compared
with survival after transplantation for similar patients. For this, pa-
tients who underwent transplantation as UNOS status 2 were
matched with delisted patients on age, sex, race, UNOS status at list-
ing, diagnosis at listing, transplantation date, and waiting time to
transplantation or delisting by using propensity score methodol-
ogy.7,9 This yielded 85 matched pairs.
Results
Temporal Changes in Heart Failure Severity
During follow-up, 30 of 100 patients delisted for medical im-
provement had return of heart failure. Of these, only 8 were
relisted (5 subsequently transplanted), and 15 died of heart
failure. Six others had medical contraindications to transplan-
tation, and importantly, the remaining patients were not
referred back to a transplantation center to be reevaluated
for transplantation as their heart failure worsened.
Risk of return of heart failure increased rapidly to 3.5%
per year and then rose more slowly thereafter—but never lev-
eled off or decreased—such that by 5 years it was nearly dou-The Journal of Thorble that at 1 year (7.2% per year). This resulted in freedom
from return of heart failure at 1, 5, and 10 years of 97%,
77%, and 51%, respectively (Figure 1). The only incremental
risk factor for return of heart failure was older age at delisting
(Table 2).
Sudden Cardiac Death
SCD was the most common mode of death, occurring in 26
patients. Risk of SCD peaked about 2.5 years after delisting
at 10% per year and then decreased to a constant rate of 3.5%
per year (Figure 2). As a result, freedom from SCD at 1, 5,
and 10 years was 96.5%, 75%, and 62%, respectively. Incre-
mental risk factors for SCD were ischemic cardiomyopathy
Figure 1. Freedom from return of heart failure (HF; return to New
York Heart Association Class IV, relisting for transplantation, im-
plementation of mechanical circulatory support, or death from
heart failure). Each symbol represents a death positioned actuar-
ially, vertical bars are 68% confidence limits, and numbers in pa-
rentheses are patients remaining at risk. The solid line is the
parametric estimate enclosed within dashed 68% confidence
limits.
TABLE 2. Incremental risk factors for events after delisting
for medical improvement
Event and risk factors Coefficient 6 SE P value
Return of heart failure
Older age at delisting* 1.47 6 0.48 .002
Sudden cardiac death
Ischemic cardiomyopathy 1.49 6 0.63 .02
Earlier in experiencey 20.33 6 0.098 .0006
All-cause mortality
Older age at delisting* 1.18 6 0.36 .001
Longer time on waiting list 0.31 6 0.13 .02
Earlier in experiencez 21.00 6 0.25 ,.0001
SE, Standard error. *(Age/50)2, squared transformation. yYears to delisting
since 1985. zLn(years to delisting since 1985), logarithmic transformation.acic and Cardiovascular Surgery c Volume 135, Number 5 1161
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2). ICD insertion was not the standard of care for much of the
study time frame; thus, at delisting, only 1 patient had an
ICD, but during the course of patient follow-up, 18 under-
went ICD implantation.
Event-free Survival
Risk of death in noncardiac modes increased moderately up
to 3 to 4 years and then slowly decreased (Figure 3, A). If
one then combines the competing risks of return of heart fail-
ure, SCD, and noncardiac death, event-free survival at 1, 5,
and 10 years after delisting was 94%, 55%, and 28%, respec-
tively (Figure 3, B). If one assumes 100% effectiveness of
ICDs in preventing SCD, we estimated by means of simula-
tion that event-free survival would have been 97%, 73%, and
45%, respectively (Figure 4).
Survival and Comparison With Transplantation
During follow-up, 58 patients died. Survival of patients at 1,
5, and 10 years was 93%, 63%, and 35%, respectively, with
a median time to death of 7 years (Figure 5). Incremental risk
factors for death included older age at delisting, longer dura-
tion on the waiting list, and delisting earlier in the experience
(particularly within the first 5 years). Among 85 propensity-
matched pairs, survival was better for about 18 months for
delisted patients than for those undergoing transplantation
in status 2 because of the high early risk of transplantation
(Figure 6). After about 30 months, survival was demonstra-
bly better after transplantation (confidence limits nonoverlap-
ping). Thus, at 5 and 10 years, survival after transplantation
of status 2 patients was 85% and 70%, respectively, com-
pared with 63% and 36%, respectively, for matched delisted
status 2 patients.
Figure 2. Risk of sudden death after delisting among patients
without an implantable cardioverter2defibrillator. Dashed lines
represent 68% confidence limits.1162 The Journal of Thoracic and Cardiovascular Surgery c MaDiscussion
Principal Findings
Approximately one third of patients removed from the heart
transplant waiting list for medical improvement experienced
return of heart failure, most dying without transplantation,
but SCD was the leading cause of death. Short-term survival
was better than that for patients undergoing transplantation
(up to 18 months), but in the long-term, return of heart failure
symptoms, SCD, and death from heart failure began exacting
a heavy toll. After delisting, systematic follow-upwith a heart
failure specialist and ICD insertion might have substantially
improved outcomes.
Temporal Changes in Heart Failure Severity
An increase in peak _VO2 levels that occurred during listing,
which might have been due to the intensity of therapy in such
Figure 3. Competing risks after delisting for medical improve-
ment. A, Rates of transition from event-free survival to heart fail-
ure, sudden cardiac death, or death from other causes. B,
Resulting proportion of patients in each state (event-free survival,
heart failure, sudden cardiac death, or other modes of death)
across follow-up.y 2008
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dictive of late outcomes. Favorable short-term outcomes (,2
years) in listed patients who increased their _VO2 levels has
also been reported in some,10,11 but not all,12 series. The 9 pa-
tients listed for cardiogenic shock and requiring temporary
mechanical circulatory support all had dramatic return of
cardiac function and were subsequently delisted.
Risk of return of heart failure symptoms increased rapidly
within a year of delisting and then slowly but steadily contin-
ued to increase. Late return of heart failure symptoms is not
surprising because heart failure is a chronic and progressive
disease. Importantly, follow-up care, especially with regard
to contemporary disease management, was neither system-
atic nor intensive. Only 5% of patients were followed by
a heart failure specialist after delisting; thus, the levels of
Figure 4. Simulated improvement in event-free survival of patients
were sudden cardiac death to be eliminated by inserting implant-
able cardioverter2defibrillators (ICD). Parametric survival curves
are formatted as for Figure 1, except parametric confidence limits
are not shown.
Figure 5. Survival of medically improved patients after delisting.
Format is as in Figure 1.The Journal of Thorcare and compliance with heart failure therapies were un-
known, and critically, the majority of patients who returned
to NYHA class IV heart failure were not referred back to
our transplantation center. Previous studies, as well as recent
data, suggest that outcomes are improved by the attentive
care provided within a heart failure disease management
program.13-15
Sudden Cardiac Death
SCD was the most common mode of death for these patients,
accounting for 45% of deaths. By means of simulation, we
estimated that an ICD would have substantially improved in-
termediate and long-term event-free survival in this popula-
tion after delisting because it clearly affects a mechanism
of death not captured by improved functional capacity or ex-
ercise tolerance. Results of this simulation are similar to those
observed in the Multicenter Automatic Defibrillator Implan-
tation Trial II study of ICD therapy in patients with prior
myocardial infarction and reduced left ventricular function,
as well as in clinical studies of stable heart transplant candi-
dates.16-18 Beyond optimal medical therapy, the Sudden Car-
diac Death in Heart Failure Trial demonstrated a 46% relative
reduction in the risk of SCD in NYHA class II patients with
an ICD and further explains the high risk of SCD in our stable
heart failure group, patients who, for the most part, did not
have an ICD.19
In a recent analysis of 50,000 UNOS registrants awaiting
heart transplantation between 1990 and 2005, the presence of
an ICD in status 1 candidates on the day of listing correlated
with improved outcomes.20 This same study demonstrated
that 1-year survival of non-transplanted status 2 candidates
in the most recent era (2000–2005) is approaching that of sur-
vival after transplantation. Although the authors were unable
Figure 6. Comparison of survival of medically improved patients
after delisting (circles) to propensity-matched Unified Network
for Organ Sharing status 2 patients after cardiac transplantation
(squares). Format is as in Figure 1.acic and Cardiovascular Surgery c Volume 135, Number 5 1163
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comes, it is important to note that in the most recent era,
47% of listed status 2 patients had an ICD compared with
18% between 1995 and 1999 and 0% between 1990 and
1994.
Although the results of the Multicenter Automatic Defi-
brillator Implantation Trial II and Sudden Cardiac Death in
Heart Failure Trial in NYHA class II patients are well known,
and furthermore, ICD implantation is a class IA recommen-
dation from the 2006 American College of Cardiology/
American Heart Association/European Society of Cardiol-
ogy guidelines,21 Lietz and Miller20 have shown that even
in the most recent era, fewer than half of status 2 patients
on the UNOS waiting list had ICDs. The ominous findings
of SCD in our own study clearly demonstrate the need for
ICDs in these ‘‘low-risk’’ patients.
Survival
Recent studies question whether cardiac transplantation pro-
vides a survival benefit over optimal medical therapy in status
2 patients.1,2 To date, all published survival data comparing
medical management of transplant candidates with trans-
planted patients are limited by follow-up of only 1 to 5
years.10,11,22,23 The strength of our investigation is the 10-
year follow-up. If one assumes that our delisted patients
were the healthiest or lowest-risk patients, their survival
should be better than that of the average status 2 patient after
transplantation, and in our experience this is in fact the case
out to at least 18 months. However, heart failure and SCD es-
calate thereafter, and data from both our study and prior in-
vestigations are insufficient to predict who will deteriorate
over time.
Limitations
This is a nonrandomizedobservational study encompassing20
years of experience from a single high-volume transplantation
center but involving a relatively small number of patients. Nu-
merous changes in clinical management occurred during this
time, and multiple surgeons and cardiologists were involved
in caring for these patients. Unfortunately, we were unable
to quantify the intensity andquality of care after delisting to de-
termine how these might have affected outcome. Major ad-
vances in medical and device therapies occurred as well,
including use of b-blockers, ICDs, cardiac resynchronization
therapy, and dissemination of evidence-based care. Impor-
tantly, because of improved survival in patients treated with
b-blockers, the traditional cutoff point of less than 14 mg $
kg21 $ min21 for transplantation is being reassessed; a value
of less than 12 mg $ kg21 $min21 might be more appropriate.
Clinical Implications and Recommendations
for Practice Guidelines
Although the outcomes of this study cannot be extrapolated
to all status 2 transplant candidates, and we do not believe1164 The Journal of Thoracic and Cardiovascular Surgery c Mit to be a direct substitute for a trial of tailored medical ther-
apy versus transplantation, we believe our findings have sev-
eral implications for both status 2 patients and those being
considered for delisting.
First, all patients meeting guideline criteria should have an
ICD implanted.
Second, follow-up must be intense and is best done by
heart failure specialists as if patients remained on the trans-
plant waiting list.
Third, close periodic surveillance (every 3–6 months) is re-
quired to identifypatientswhose cardiac function is deteriorating.
Fourth, additional methods for monitoring both listed and
delisted patients should be investigated, including implant-
able hemodynamic devices, microvolt T-wave alternans,
and biomarkers, to anticipate deterioration earlier and prompt
renewed consideration for relisting or status upgrade.
Fifth, timing of transplantation in this population remains
a dilemma. More detailed and longer-term investigation into
the prediction of survival for status 2 patients is needed, as
has already been done for status 1 patients. Reliable predic-
tive models for status 2 patients might help discriminate
low- from high-risk patients, helping to guide time of listing.
Sixth, UNOS modifications to the current allocation sys-
tem might be required when accurate predictive models be-
come available. If the number of patients listed continues
to decrease and efforts to increase organ donation are suc-
cessful, more status 2 patients might be offered organs. In
that case, one would need to balance long-term survival of
the graft and morbidity associated with long-term immuno-
suppression against good short-term survival of low-risk pa-
tients who do not undergo transplantation. Consequently, it
might be that in this situation, the lowest-risk patients should
have transplantation delayed as long as possible and undergo
transplantation only when matched to a perfect heart.
We thank Lucy Thiuta, MS, for data management and analysis
and Tess Parry for editorial assistance.
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Discussion
Dr Abbas Ardehali (Pacific Palisades, Calif). First, I want to com-
pliment Ms Hoercher for an excellent presentation, and I also want
to thank the authors for forwarding the manuscript to me several
days in advance of this meeting.The Journal of ThoraThis is a timely study that investigates the outcome of 100 status
2 patients who are removed from the transplant list because of med-
ical improvement. The strength of this article is the long-term fol-
low-up for 10 years. There were 3 major findings. First, the risk
of return of heart failure or sudden cardiac death was about 3% to
5% per year. Second, survival of this cohort was 93% at 1 year
but decreased precipitously at 5 years to 63% and at 10 years to
35%. Third, when compared with a contemporaneous cohort of
status 2 patients who underwent transplantation, the early survival
of the delisted patients was better, but the survival curves crossed
at 18 months. The status 2 patients who underwent transplantation
had a better survival at 5 and 10 years.
This report contains some good news and some bad news. The
good news is that the highly selected patients who were function-
ally improved can be removed from the waiting list safely, and
for the most part, they do okay in the short term. The bad
news is that most of these patients do poorly in the long term
and can still benefit from heart transplantation, which brings me
to 3 questions.
First, given these findings, how have you modified your ap-
proach to delisting patients, what are your protocols for monitoring
the delisted patients, and at what frequency and at which center are
they delisted?
Ms Hoercher. First, I would like to say that we are listing far
fewer patients now than even 10 years ago. This is indeed a reflection
of the expanded options available both medically and surgically.
Based on these findings, we monitor patients who are listed much
more closely and restage them every 6 months. For patients who
are listed as status 2 and do show signs of medical improvement,
we initially change them to status 7 before removing them from
the list completely. This encourages them to return to see us every
3 to 6 months, at which time we repeat their metabolic stress tests,
right heart catheterizations, echocardiographic analyses, and labora-
tory work-ups. Therefore, I would say that the findings of this study
had a major effect on the way we care for this cohort of patients.
De Ardehali. So all the inactivated patients are brought back to
Cleveland Clinic.
Ms Hoercher. That is correct. One of the key findings was the
loss of follow-up for patients we removed over the past 20 years.
We believe that if they had been followed by a heart failure specialist
using evidence-based guidelines, this could have made a big differ-
ence in survival. Of course, the sobering finding of the high preva-
lence of sudden cardiac death in this group, coupled with such a low
ICD use rate, has changed our practice in this area as well. All pa-
tients whomeet the guidelines, whether they are delisted for medical
improvement or status 2 patients waiting at home, receive ICDs.
In addition, many are now having ICDs combined with cardiac
resynchronization therapy.
Dr Ardehali. So your recommendation is to bring the patients
back to the transplantation center, have them followed by the heart
failure specialist at the transplantation center, and treat them accord-
ing to the guidelines of the transplantation center.
Ms Hoercher. That is correct.
Dr Ardehali. Second, several studies have shown that the sur-
vival of status 2 patients undergoing heart transplantation is similar
to that of those remaining on the waiting list, at least for the short
term, maybe 1 to 3 years. As a result, some authorities in the heart
transplantation community have suggested that it is time forcic and Cardiovascular Surgery c Volume 135, Number 5 1165
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with optimized medical therapy in status 2 patients. Given your find-
ings, do you think such a study is rational, or do you think we should
just look at the Scientific Registry of Transplant Recipients data-
base, maybe at 5 or 10 years out?
Ms Hoercher. I do not think we should be looking at data from
the Scientific Registry of Transplant Recipients at 5 and 10 years un-
less the data collected become much more robust. For example, we
do not know whether patients who are listed as status 2 in the Scien-
tific Registry of Transplant Recipients database have ICDs, nor do
we know their medical therapy, and therefore I do not think that
these data would answer the question of transplantation versus med-
ical therapy.
As far as the other studies you reference, I think we need to see
what their results look like in 5 years before calling for a randomized
trial.
DrArdehali. Finally, as you know, the thoracic organ committee
of UNOS is now considering a new heart allocation system, a system
that incorporates thewait list mortality versus the posttransplantation
1-year survival, which is very similar to the lung allocation score.
Given the findings of the study, is arbitrary 1-year survival, which
has been the benchmark for the lung allocation score and continues
to be the foundation for the allocation system now, valid? Is it ratio-
nal, or should we be looking at the 5-year survival of heart transplant
recipients?
Again, congratulations on an important study and a good presen-
tation.
Ms Hoercher. Thank you. Arbitrary 1-year transplantation sur-
vival is not a rational criterion when making a decision regarding
heart allocation for transplantation. A better guide would be an abil-
ity to determine the difference between expected outcomes with and
without transplantation. I think that once again, you need to balance
the risks and benefits. Certainly, looking at 1-year survival is not
enough; we need to look at 5-year survival as well. But I also think
that we are so focused on survival in this country that we often forget
to consider quality of life. All of us see our patients alive at 18 to 20
years after transplantation, but I see my patients missing lower ex-
tremities, receiving chronic dialysis, and battling cancer, to name
just a few posttransplantation morbidities. Survival alone is not
enough, which is why I think you need to defer transplantation for
your stable status 2 patients as long as possible.
Dr Joseph Cleveland (Denver, Colo). That was a very nice pre-
sentation, and as always, data from Cleveland Clinic have helped
guide a lot of things.
I have 2 questions. First, do you think status 2 patients are equiv-
alent? In other words, one of the things that we wrestle with in1166 The Journal of Thoracic and Cardiovascular Surgery c MColorado is what defines a status 2 patient. I would probably venture
that a status 2 patient in Cleveland might look different than a status
2 patient in Denver, who might look different than a status 2 patient
in Los Angeles. Some of it has to do with how quickly organs are
offered, for example.
Second, what do you think the effect of ventricular assist device
therapymight play in this, particularly with the more recent encourag-
ing reports with destination therapy. Could this then again be, if you
will, with newer-generation devices, selected patients now having sur-
vival at 3 and 5 years of perhaps 70% in centers and other places these
patients can go, because I think the sobering part of your presentation
is what happens to these patients long term. I would agree that having
them followed in a center of heart failure transplantation excellence is
part of it and that this might also be a place where destination therapy
might play a role. I would be curious to hear your thoughts.
Ms Hoercher. I agree with you that a status 2 patient at Cleve-
land Clinic might not be the same as a status 2 patient elsewhere.
That is why UNOS needs to start collecting data on medical therapy,
whether patients have CRT, and whether they have ICDs. I also
think that our patients who were delisted for medical improvement
might have been a sicker group than patients elsewhere.
Your second question was about the role of destination therapy.
I do not believe that there is a role for mechanical support in status
2 patients. Although there is increasing evidence for left ventricular
assist devices earlier in the disease course and before the develop-
ment of end-organ failure, at this time, patients who require inotro-
pic support appear to derive the greatest benefit. It remains to be
seen whether those less severely ill patients not receiving inotropic
support, the status 2 patients, would gain a survival benefit from left
ventricular assist device therapy over that of optimal medical ther-
apy.
Dr John Benfield (Los Angeles, Calif). This is a very important
and thought-provoking paper. Listing, delisting, and selection of pa-
tients for transplantation is an awesome responsibility, and we must
acknowledge that we are not always right. What are your thoughts
about the priority on the transplant list that should be afforded to
or given to delisted patients whose status changes such that they
then again become candidates for transplantation?
Ms Hoercher. That is an excellent question. As a result of this
study, I am wondering whether UNOS should split status 2 into
2a and 2b. Then instead of delisting patients, they could be listed
as 2b, recognizing that such patients would not undergo transplan-
tation for a long time. Again, a key finding of this study is the impor-
tance of close monitoring of these patients. By keeping a patient on
the UNOS list, both the patient and the transplantation center would
likely be more compliant with follow-up.ay 2008
